ArticleFrontiers in endocrinology2025
Hashimoto's thyroiditis in an Egyptian cohort: clinical, functional, and ultrasonographic features with insights into nodule risk.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Assessment of malignant risk in thyroid nodules classified as category 4 and above against a background of Hashimoto's thyroiditis.Gland surgery · 2026Article
- Development and validation of a multimodal predictive model based on clinical, biochemical, and quantitative dual-energy CT parameters: for predicting the benignity and malignancy of thyroid nodules.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Hashimoto's thyroiditis (HT) is a highly prevalent autoimmune disorder. Its coexistence with benign and malignant thyroid nodules is well-documented; however, data from non-Western countries remain limited. Our objectives were to determine the demographics, clinical presentation, biochemical parameters, and thyroid ultrasonographic findings in an Egyptian cohort with HT; estimate nodule prevalence; and identify potential risk factors for nodular presentation. Patients and methods: A cross-sectional study was conducted on 408 newly diagnosed patients with HT at Alexandria University Hospital. Sociodemographic, clinical presentation, biochemical (thyroid function and autoantibodies thyroperoxidase and thyroglobulin Abs), and ultrasonographic data were collected. Thyroid nodules were classified according to the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS). Fine-needle aspiration cytology (FNAC) was classified by the Bethesda system (BSRTC). Multiple logistic regression identified predictors of nodularity. Results: Among our cohort of 408 participants (female-to-male ratio of 15:1; mean age 38.6 years), 23.5% had thyroid nodules on ultrasound. Nodules were more frequent in those ≥35 years and with a family history of thyroid disease. Compressive symptoms were more common in the nodular group (33.0% vs. 18.6%). Hypothyroidism was observed in 80.9%, predominantly subclinical, and was more frequent in the non-nodular group (80.4% vs. 71.1%). Autoantibodies tested positive in 87.5%. One-third had diffuse enlargement; most nodules were classified as TIRADS 3 or 4. FNAC ( Conclusion: HT shows heterogeneous clinical presentations, with subclinical hypothyroidism predominating. Compressive symptoms are more common in patients with nodules. Ultrasound and FNAC are essential for the management of nodules with HT and can help prevent unnecessary surgery. Older age, larger thyroid volume, and a positive familial history of goiter and/or thyroid cancer are major predictors for nodularity. The malignancy rate is ~2%, with microcalcifications strongly associated with malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.